| The developmental pathway for CD103+ CD8+ tissue-resident memory T cells of skin LK Mackay, A Rahimpour, JZ Ma, N Collins, AT Stock, ML Hafon, ... Nature immunology 14 (12), 1294-1301, 2013 | 734 | 2013 |
| Enhanced antitumor immunity in mice deficient in CD69 E Esplugues, D Sancho, J Vega-Ramos, C Martínez-A, U Syrbe, ... The Journal of experimental medicine 197 (9), 1093-1106, 2003 | 188 | 2003 |
| DEC-205 is a cell surface receptor for CpG oligonucleotides MH Lahoud, F Ahmet, JG Zhang, S Meuter, AN Policheni, S Kitsoulis, ... Proceedings of the National Academy of Sciences 109 (40), 16270-16275, 2012 | 139 | 2012 |
| Induction of tumor NK-cell immunity by anti-CD69 antibody therapy E Esplugues, J Vega-Ramos, D Cartoixà, BN Vazquez, I Salaet, P Engel, ... Blood 105 (11), 4399-4406, 2005 | 73 | 2005 |
| Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination A Reuter, SE Panozza, C Macri, C Dumont, J Li, H Liu, E Segura, ... The Journal of Immunology 194 (6), 2696-2705, 2015 | 46 | 2015 |
| CD69 limits early inflammatory diseases associated with immune response to Listeria monocytogenes infection J Vega‐Ramos, E Alari‐Pahissa, J Valle, E Carrasco‐Marín, E Esplugues, ... Immunology and cell biology 88 (7), 707-715, 2010 | 44 | 2010 |
| The inflammatory cytokine, GM‐CSF, alters the developmental outcome of murine dendritic cells Y Zhan, J Vega‐Ramos, EM Carrington, JA Villadangos, AM Lew, Y Xu European journal of immunology 42 (11), 2889-2900, 2012 | 43 | 2012 |
| CD69 does not affect the extent of T cell priming E Alari-Pahissa, L Notario, E Lorente, J Vega-Ramos, A Justel, D López, ... PLoS One 7 (10), e48593, 2012 | 30 | 2012 |
| Dendritic cell migration and antigen presentation are coordinated by the opposing functions of the tetraspanins CD82 and CD37 EL Jones, JL Wee, MC Demaria, J Blakeley, PK Ho, J Vega-Ramos, ... The Journal of Immunology 196 (3), 978-987, 2016 | 29 | 2016 |
| Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets KA Markey, M Koyama, RD Kuns, KE Lineburg, YA Wilson, SD Olver, ... Blood 119 (24), 5918-5930, 2012 | 29 | 2012 |
| Inflammation conditions mature dendritic cells to retain the capacity to present new antigens but with altered cytokine secretion function J Vega-Ramos, A Roquilly, Y Zhan, LJ Young, JD Mintern, JA Villadangos The Journal of Immunology 193 (8), 3851-3859, 2014 | 24 | 2014 |
| Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system Y Xu, P Lindemann, J Vega-Ramos, JG Zhang, JA Villadangos Journal of Biological Chemistry 289 (14), 9730-9740, 2014 | 23 | 2014 |
| Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals J Vega-Ramos, A Roquilly, K Asehnoune, JA Villadangos Current opinion in pharmacology 17, 64-70, 2014 | 22 | 2014 |
| Consequences of direct and indirect activation of dendritic cells on antigen presentation: functional implications and clinical considerations J Vega-Ramos, JA Villadangos Molecular immunology 55 (2), 175-178, 2013 | 20 | 2013 |
| Differential effect of CD69 targeting on bystander and antigen‐specific T cell proliferation E Alari‐Pahissa, J Vega‐Ramos, JG Zhang, AR Castaño, SJ Turley, ... Journal of leukocyte biology 92 (1), 145-158, 2012 | 20 | 2012 |
| Serpinb9 (Spi6)‐deficient mice are impaired in dendritic cell‐mediated antigen cross‐presentation A Rizzitelli, S Meuter, J Vega Ramos, CH Bird, JD Mintern, MSJ Mangan, ... Immunology and cell biology 90 (9), 841-851, 2012 | 17 | 2012 |
| Serpinb9 is a marker of antigen cross-presenting dendritic cells MS Mangan, J Vega-Ramos, LT Joeckel, AJ Mitchell, A Rizzitelli, ... Molecular immunology 82, 50-56, 2017 | 11 | 2017 |
| 578 Lauzurica P, Mueller SN, Stefanovic T, Tscharke DC, Heath WR, Inouye M, Carbone FR, 579 Gebhardt T. 2013. The developmental pathway for CD103 (+) CD8+ tissue-resident 580 … LK Mackay, A Rahimpour, JZ Ma, N Collins, AT Stock, ML Hafon, ... Nat Immunol 14, 1294-301, 0 | 6* | |
| Shutdown of immunological priming and presentation after in vivo administration of adenovirus RM Sutherland, SL Londrigan, JL Brady, H Azher, EM Carrington, Y Zhan, ... Gene therapy 19 (11), 1095-1100, 2012 | 3 | 2012 |
| Methods Of Treating Viral Hepatitis F Sanchez-Madrid, CM Alonso, DS Madrid, PE Rocamora, EE Artola, ... US Patent App. 12/944,432, 2011 | 1 | 2011 |
Jose A. VilladangosThe University of MelbourneVerified email at unimelb.edu.au
